Case study
Overview
A rapidly growing, biopharmaceutical company, dedicated to developing innovative therapies and novel biologics for rare and underserved ocular disorders, aggressively pursues new treatments for ocular surface diseases, retinal diseases as well as a gene therapy pipeline.
- Study Phase: III
- Indication: Dry Eye Disease
- Sites: 25
- Services: Full Service
Challenges
- To initiate 25 sites in the US within 4 weeks
- To randomize 250 patients within 6 weeks
- To clean all data within 1 week of Last Patient Out
- To deliver Top Line Results within 3 weeks of Last Patient Out
